Latest:
The Era of Interrogating Single Cells in Cancer Biopsy Is Now
Even in seemingly uniform cell populations within subcompartments, cell-cell heterogeneity is becoming more evident, far beyond what was previously expected.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Nancy B. David, MD
Latest:
Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer
The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.
Nancy B. Gordon, MD
Latest:
Dr. Gordon on Toxicities With Immunotherapy in Osteosarcoma
Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.
Nancy E. Kemeny, MD
Latest:
Hepatic Infusion Can Convert CRC Liver Metastases to Operable State
Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.
Nancy Fell Hill, MPH
Latest:
The ABCs of IRBs: A Brief Overview
At some point in their careers, most oncologists will need to submit a research proposal to their hospital's Institutional Review Board. Too many physicians view the IRB process as an additional bureaucratic burden in their already overloaded daily schedules.
Nancy Lee, MD
Latest:
Novel Approach Reduces Treatment Toxicities in Patients With HPV-Related Oropharyngeal Cancer
The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.
Nancy U. Lin, MD
Dr. Lin serves as associate chief of the Division of Breast Oncology at Dana-Farber. She is the founder and director of the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases.
Latest:
Advancing Brain Metastases Research and Mentorship in Breast Oncology: With D. Ross Camidge, MD, PhD; Nancy U. Lin, MD
Drs Camidge and Lin discussed Dr Lin's work with brain metastases and her role in developing targeted therapies for breast cancer.
Naomi B. Haas, MD
Naomi B. Haas, MD, is the director of the Prostate and Kidney Cancer Program at the Abramson Cancer Center;as well as a professor of medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania.
Latest:
Dr Haas on the Rationale for Evaluating Adjuvant Pembrolizumab in Clear Cell RCC
Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.